Autocrine PDGF stimulation in malignancies

Upsala Journal of Medical Sciences

Volumn 117, Issue 2, 2012, Pages 83-91

  Heldin, Carl Henrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Molecular biology; Oncogenes; Tumor biology

Indexed keywords

ANTINEOPLASTIC AGENT; ISOPROTEIN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; MUTATION; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; MUTATION; NEOPLASMS; ONCOGENE PROTEINS V-SIS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN ISOFORMS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 84859890474     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2012.658119     Document Type: Review

References (107)

1. Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79: 1283-316. (Pubitemid 29473317)
2. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22:1276-312. (Pubitemid 351717519)
3. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet. 1992;339:23-5.
4. Rodt SÅ, Åhlén K, Berg A, Rubin K, Reed RK. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol. 1996;495:193-200. (Pubitemid 26288464)
5. Antoniades HN, Scher CD, Stiles CD. Purification of human platelet-derived growth factor. Proc Natl Acad Sci USA. 1979; 76:1809-12.
6. Deuel TF, Huang JS, Proffitt RT, Baenziger JU, Chang D, Kennedy BB. Human platelet-derived growth factor: purification and resolution into two active protein fractions. J Biol Chem. 1981;256:8896-9. (Pubitemid 12208291)
7. Heldin C-H, Westermark B, Wasteson Å. Platelet-derived growth factor: purification and partial characterization. Proc Natl Acad Sci USA. 1979;76:3722-6. (Pubitemid 9246448)
8. Raines EW, Ross R. Platelet-derived growth factor. I. High yield purification and evidence for multiple forms. J Biol Chem. 1982;257:5154-60. (Pubitemid 12054836)
9. sis of simian sarcoma virus. Nature. 1983;304: 35-9. (Pubitemid 13063102)
10. Doolittle RF, Hunkapiller MW, Hood LE, Devare SD, Robbins KC, Aaronson SA, et al. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science. 1983;221:275-7. (Pubitemid 13062620)
11. Deuel TF, Huang JS, Huang SS, Stroobant P, Waterfield MD. Expression of a platelet-derived growth factor-like protein in simian sarcoma virus transformed cells. Science. 1983;221:1348-50. (Pubitemid 13006125)
12. Johnsson A, Betsholtz C, von der Helm K, Heldin C-H, Westermark B. Platelet-derived growth factor agonist activity of a secreted form of the v-sis oncogene product. Proc Natl Acad Sci USA. 1985;82:1721-5. (Pubitemid 15079464)
13. Johnsson A, Betsholtz C, Heldin C-H, Westermark B. Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus. Nature. 1985;317: 438-40. (Pubitemid 15242593)
14. Heldin C-H, Westermark B. Growth factors: mechanism of action and relation to oncogenes. Cell. 1984;37:9-20. (Pubitemid 14079832)
15. Temin HM, Pierson RW Jr, Dulak NC. The role of serum in the control of multiplication of avian and mammalian cells in culture. In Rothblatt GH, Cristofalo VJ, editors. Growth, nutrition and metabolism of cells in culture. New York: Academic Press; 1972. p 50-81.
16. Heldin C-H, Westermark B, Wasteson Å. Chemical and biological properties of a growth factor from human-cultured osteosarcoma cells: resemblance with platelet-derived growth factor. J Cell Physiol. 1980;105:235-46. (Pubitemid 11200134)
17. Westermark B, Wasteson Å. The response of cultured normal glial cells to growth factors. In Luft R, Hall K, editors. Advances in metabolic disorders. New York: Academic Press; 1975. p 85-100.
18. Heldin C-H, Johnsson A, Wennergren S, Wernstedt C, Betsholtz C, Westermark B. A human osteosarcoma cell line secretes a growth factor structurally related to a homo-dimer of PDGF A-chains. Nature. 1986;319:511-14. (Pubitemid 16212934)
19. Betsholtz C, Westermark B, Ek B, Heldin C-H. Coexpression ofa PDGF-like growth factor and PDGF receptorsin ahuman osteosarcoma cell line: implications for autocrine receptor activation. Cell. 1984;39:447-57. (Pubitemid 15198584)
20. Nistér M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin C-H, et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-a and their receptors in human malignant glioma cell lines. Cancer Res. 1988;48:3910-18.
21. Nistér M, Claesson-Welsh L, Eriksson A, Heldin C-H, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem. 1991;266:16755-63. (Pubitemid 21907863)
22. Vassbotn FS, Östman A, Langeland N, Holmsen H, Westermark B, Heldin C-H, et al. Activated platelet-derived growth factor autocrine pathway drives the transformed phe-notype of a human glioblastoma cell line. J Cell Physiol. 1994; 158:381-9. (Pubitemid 24063566)
23. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oli-goastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001;15:1913-25. (Pubitemid 32738621)
24. Shamah SM, Stiles CD, Guha A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol. 1993; 13:7203-12. (Pubitemid 23354243)
25. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astro-cytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 1995;60:168-73.
26. Hermanson M, Nistér M, Betsholtz C, Heldin C-H, Westermark B, Funa K. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growh factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci USA. 1988; 85:7748-52.
27. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of auto-crine and paracrine loops. Cancer Res. 1992;52:3213-19.
28. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glio-blastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002;62:3729-35. (Pubitemid 34728854)
29. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, et al. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest. 1990;86:131-40. (Pubitemid 20226985)
30. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4:e7752.
31. Lindberg N, Holland E. PDGF in gliomas: more than just a growth factor? Ups J Med Sci. 2012;117:92-8.
32. Smits A, Funa K, Vassbotn FS, Beausang-Linder M, af Ekenstam F, Heldin C-H, et al. Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am J Pathol. 1992;140:639-48.
33. Wang J, Coltrera MD, Gown AM. Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study. Cancer Res. 1994;54:560-4.
34. Stürzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA. 1992;89:7046-50.
35. Maxwell M, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer. 1990;46:16-21. (Pubitemid 20225781)
36. Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996;84:852-8.
37. Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood. 2010;115:51-60.
38. Ghanem M, Nijman R, Safan M, van der Kwast T, Vansteenbrugge G. Expression and prognostic value of platelet-derived growth factor-AA and its receptor a in nephroblastoma. BJU Int. 2010;106:1389-93.
39. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-a activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009;69:3937-46.
40. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008;27: 6550-60.
41. Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer. 2007;110: 2293-303. (Pubitemid 350100752)
42. O'Brien KP, Seroussi E, Dal Cin P, Sciot R, Mandahl N, Fletcher JA, et al. Various regions within the a-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibro-blastomas. Gene Chrom Cancer. 1998;23:187-93. (Pubitemid 28402346)
43. Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, et al. The dermatofibrosarcoma protuberans-associated collagen type Ia1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999; 59:3719-23. (Pubitemid 29381878)
44. Simon M-P, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre J-M, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15:95-8. (Pubitemid 27014958)
45. Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, et al. Growth inhibition of dermatofibrosar-coma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001;61:5778-83. (Pubitemid 32769094)
46. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004;15:197-204. (Pubitemid 38781045)
47. Ustach CV, Kim HR. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol. 2005;25:6279-88. (Pubitemid 40946575)
48. Keating MT, Williams LT. Autocrine stimulation of intracel-lular PDGF receptors in v-sis transformed cells. Science. 1988;239:914-16. (Pubitemid 18065433)
49. Huang SS, Huang JS. Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation. J Biol Chem. 1988;263:12608-18. (Pubitemid 19000444)
50. Bejcek BE, Li DY, Deuel TF. Transformation by v-sis occurs by an internal autoactivation mechanism. Science. 1989;245: 1496-9. (Pubitemid 19243240)
51. Betsholtz C, Johnsson A, Heldin C-H, Westermark B. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci USA. 1986;83:6440-4. (Pubitemid 17174750)
52. Hannink M, Donoghue DJ. Autocrine stimulation by the v-sis gene product requires a ligand-receptor interaction at the cell surface. J Cell Biol. 1988;107:287-98.
53. Huang JS, Huang SS, Deuel TF. Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors. Cell. 1984;39:79-87. (Pubitemid 15218227)
54. Valgeirsdóttir S, Eriksson A, Nistér M, Heldin C-H, Westermark B, Claesson-Welsh L. Compartmentalization of autocrine signal transduction pathways in Sis transformed NIH 3T3 cells. J Biol Chem. 1995;270:10161-70.
55. Afrakhte M, Nistér M, Östman A, Westermark B, Paulsson Y. Production of cell-associated PDGF-AA by a human sarcoma cell line: evidence for a latent autocrine effect. Int J Cancer. 1996;68:802-9. (Pubitemid 27062044)
56. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellström M, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003;17:1835-40. (Pubitemid 36944561)
57. Ehnman M, Li H, Fredriksson L, Pietras K, Eriksson U. The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth. Oncogene. 2009;28:534-44.
58. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-16. (Pubitemid 24138627)
59. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor b receptor in chronic myelomonocytic leukemia. Blood. 2001;98:2518-25.
60. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of ima-tinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-14. (Pubitemid 36359296)
61. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA. 2003; 100:7830-5. (Pubitemid 36760055)
62. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic masto-cytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093-6. (Pubitemid 37314742)
63. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA. 2006;103:8078-83. (Pubitemid 43801055)
64. Toffalini F, Hellberg C, Demoulin J-B. Critical role of the platelet-derived growth factor receptor (PDGFR) b transmembrane domain in the TEL-PDGFRb cytosolic oncopro-tein. J Biol Chem. 2010;285:12268-78.
65. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10. (Pubitemid 36159485)
66. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, et al. Amplification and/or over-expression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 1992;52:4550-3.
67. Kumabe T, SohmaY, Kayama T, Yoshimoto T, Yamamoto T. Amplification of platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. Oncogene. 1992;7:627-33.
68. Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, Isola J, et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res. 2006;4:927-34. (Pubitemid 46121551)
69. Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendroglio-mas with grade IV anaplastic features. J Neuropathol Exp Neurol. 2000;59:495-503. (Pubitemid 30368309)
70. Arai H, Ueno T, Tangoku A, Yoshino S, Abe T, Kawauchi S, et al. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. Cancer Genet Cytogenet. 2003;146:16-21. (Pubitemid 37117429)
71. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer. 2002;34:48-57. (Pubitemid 34260596)
72. Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene. 2003;22: 722-33. (Pubitemid 36269285)
73. Östman A, Heldin C-H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001;80:1-38. (Pubitemid 33717320)
74. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623-6. (Pubitemid 34832970)
75. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866-73. (Pubitemid 46224187)
76. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with met-astatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002; 20:3586-91. (Pubitemid 34983217)
77. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-7. (Pubitemid 34879335)
78. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor receptor fusion oncogene. Blood. 2002;100:1088-91. (Pubitemid 34832647)
79. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-8. (Pubitemid 34621126)
80. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-9. (Pubitemid 46621810)
81. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60:5143-50.
82. UhrbomL, HesselagerG, Östman A, NistérM, Westermark B. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Int J Cancer. 2000;85:398-406.
83. Pietras K, Sjöblom T, Rubin K, Heldin C-H, Östman A. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3: 439-43. (Pubitemid 38340290)
84. UhrbomL, HesselagerG, NistérM, Westermark B.Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998;58: 5275-9. (Pubitemid 28551098)
85. Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF, et al. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci USA. 2004;101:11334-7. (Pubitemid 39038347)
86. Johansson FK, Goransson H, Westermark B. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene. 2005;24:3896-905. (Pubitemid 40896401)
87. Swartling FJ, Ferletta M, Kastemar M, Weiss WA, Westermark B. Cyclic GMP dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene. 2009;28:3121-31.
88. Ferletta M, Uhrbom L, Olofsson T, Ponten F, Westermark B. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B-induced gliomagenesis. Mol Cancer Res. 2007;5:891-7. (Pubitemid 47416666)
89. Tchougounova E, Jiang Y, Brasater D, Lindberg N, Kastemar M, Asplund A, et al. Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence. Oncogene. 2009;28:1537-48.
90. Wolf RM, Draghi N, Liang X, Dai C, Uhrbom L, Eklof C, et al. p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev. 2003;17:476-87. (Pubitemid 36258762)
91. CairncrossJG, UekiK, ZlatescuMC, LisleDK, FinkelsteinDM, Hammond RR, et al. Specific genetic predictors of chemo-therapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-9.
92. Bigner SH, Rasheed BK, Wiltshire R, McLendon RE. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol. 1999;1:52-60.
93. Tchougounova E, Kastemar M, Brasater D, Holland EC, Westermark B, Uhrbom L. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene. 2007;26:6289-96. (Pubitemid 47462106)
94. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-90.
95. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003;22:7155-69. (Pubitemid 37378548)
96. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 2006;116:1561-70.
97. Seymour L, Dajee D, Bezwoda WR. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat. 1993;26:247-52. (Pubitemid 23304240)
98. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest. 1997;77:431-6. (Pubitemid 27508614)
99. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene. 2006; 25:3170-85. (Pubitemid 43881558)
100. Lau CK, Yang ZF, Ho DW, Ng MN, Yeoh GC, Poon RT, et al. An Akt/hypoxia-inducible factor-1a/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res. 2009;15:3462-71.
101. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, et al. A novel signaling axis of matrip-tase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res. 2010;70:9631-40.
102. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al. Mir-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009;27:1712-21.
103. Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, et al. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene. 2005;24:6848-54. (Pubitemid 41487044)
104. Russell MR, Jamieson WL, Dolloff NG, Fatatis A. The receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene. 2009;28:412-21.
105. Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A. The receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Cancer Res. 2010; 70:4195-203.
106. Erlandsson A, Brannvall K, Gustafsdottir S, Westermark B, Forsberg-Nilsson K. Autocrine/paracrine platelet-derived growth factor regulates proliferation of neural progenitor cells. Cancer Res. 2006;66:8042-8. (Pubitemid 44299169)
107. Jiang Y, Boije M, Westermark B, Uhrbom L. PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia. 2011;13: 492-503.